Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Acute kidney injury related pregnancy (PrAKI) affects 2.0% of all pregnancies, however, in developing countries, the incidence can range from 4.2% to 15%, with over 50% caused by sepsis or obstetric hemorrhage in contrast to developed countries, where chronic hypertension, renal disease, and preeclampsia are important causes of this condition. PrAKI accounts for a substantial proportion of maternal mortality and morbidity, particularly in low-income and middle-income countries, and also adversely affect the fetus, resulting in death, premature birth and small for gestational age. It is not entirely clear how the KDIGO PrAKI stage and renal replacement therapies affect adverse maternal and fetal outcomes. The aim of our study was to compare adverse maternal and fetal outcomes in patients with PrAKI and to identify the most common indications and modalities of renal replacement therapies in these patients.
Retrospective cohort of patients with PrAKI adverse maternal outcomes (cesarean section, miscarriage, preterm delivery, and preeclampsia) and fetal outcomes (percentage of live births, low birth weight, admission to the neonatal intensive care unit (NICU), and neonatal death) were identified. Maternal and fetal outcomes were compared according to the KDIGO PrAKI stage, additionally, the most frequent indications for initiating renal replacement therapy and the most commonly used treatment modality were identified. Descriptive statistics and chi-square tests were used for analysis, with a p-value <0.05 considered significant.
We reviewed 70 episodes of PrAKI in 70 pregnant women with a mean age of 28.97 ± 5.72 years. PrAKI occurred in 2 cases (2.9%) during the first trimester, 7 cases (10.0%) during the second trimester, 53 cases (75.7%) during the third trimester, and 8 cases (11.4%) during the postpartum period, a total of 22 episodes (31.4%) were classified as KDIGO stage 1, 22 cases (31.4%) as KDIGO stage 2, and 26 cases (37.2%) as KDIGO stage 3. The renal replacement therapy was required in 16 patients (22.9%). Intermittent hemodialysis was the most commonly used therapy (15 cases, 93.75%). Indications for initiating renal replacement therapy included volume overload (6 cases, 37.5%), elevated BUN (5 cases, 31.3%), metabolic acidosis (4 cases, 25.0%), and hypercalcemia (1 case, 6.3%). Early recovery was observed in 12 cases (17.1%), late recovery in 33 patients (47.1%), acute kidney disease in 21 cases (30.0%), and chronic kidney disease in 4 patients (5.7%). Among maternal outcomes, cesarean section occurred in 53 cases (80.3%), preterm delivery in 48 cases (75.0%), preeclampsia in 35 cases (53.0%), and miscarriage in 4 patients (5.7%). Regarding fetal outcomes, the live birth rate was 86.4% (57 cases), low birth weight occurred in 43 cases (69.4%), NICU admission in 38 cases (64.4%), and neonatal death in 7 cases (11.7%). Although the number of adverse outcomes per patient was higher in KDIGO stage 2 (2.30 ± 0.73 maternal outcomes and 1.68 ± 1.00 fetal outcomes), the difference was not significant. No significant differences were observed when comparing adverse outcomes across KDIGO stages.
In patients with PrAKI, the most commonly used renal replacement therapy was intermittent hemodialysis. However, no significant difference was observed in adverse maternal and fetal outcomes in relation to the KDIGO stages.
